Table 3.
Neutralizing antibody estimated GMTs after the 50-µg mRNA-1273.211 and the 50-µg mRNA-1273 booster doses
| Day after booster dose | mRNA-1273.211 50-µg booster dose GMTa (95% CI) | mRNA-1273 50-µg booster dose GMTa (95% CI) | GMR |
|---|---|---|---|
| Ancestral SARS-CoV-2 with D614G | |||
| Day 29 | 2,278.0 (2,074.0–2,502.1) | 1,782.7 (1,561.3–2,035.6) | 1.28 (1.08–1.51) |
| Day 181 | 1,039.9 (926.4–1,167.3) | 617.2 (525.1–725.5) | 1.68 (1.38–2.06) |
| Beta | |||
| Day 29 | 1,095.3 (981.1–1,222.7) | 825.6 (706.6–964.7) | 1.33 (1.09–1.61) |
| Day 181 | 343.5 (303.7–388.5) | 125.2 (105.4–148.8) | 2.74 (2.22–3.40) |
| Omicron | |||
| Day 29 | 1,379.3 (1,209.9–1,572.4) | 636.7 (529.1–766.3) | 2.17 (1.73–2.72) |
| Day 181 | 308.0 (265.8–356.9) | 133.0 (108.2–163.6) | 2.32 (1.80–2.98) |
| Delta | |||
| Day 29 | 1,483.0 (1,335.9–1,646.3) | 838.8 (724.4–971.2) | 1.77 (1.48–2.12) |
| Day 181 | 492.9 (438.3–554.2) | 400.8 (340.4–471.8) | 1.23 (1.01–1.50) |
The number of participants was 282–295 for the mRNA-1273.211 group and 146–149 for the mRNA-1273 group.
aGMTs were estimated GLSM titers with an MMRM adjusting for age groups and pre-booster titer levels. The key measurements (bolded) of GMRs are for the estimated GMT after the 50-µg mRNA-1273.211 booster dose relative to the estimated GMT after the 50-µg mRNA-1273 booster dose. (Superiority).